welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Guides & Guidelines
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
source: National Institute for Health and Care Excellence
year: 2016
summary/abstract:This guidance is not intended to affect the position of patients whose treatment with ataluren was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.
read morerareRelated
-
PTC Therapeutics Phase III Duchenne Muscular Dystrophy (DMD) Clinical TrialPTC Therapeutics, Inc. is seeking pa...
-
Clinical trial shows some promise for Duchenne muscular dystrophy drugThe results of an international clinical...
-
Safety and Tolerability of Ataluren in a Phase 3 Study of Patients with Nonsense Mutation Duchenne Muscular Dystroph...Objective: Examine the safety/tolerabil...
-
Design of a phase 3 trial to evaluate the long-term efficacy and safety of ataluren in patients with nonsense mutati...Ataluren is conditionally approved by th...
-
Boy with muscular dystrophy writes heartfelt note to Scottish leaderMichael Young, 9, wrote a letter to Scot...
-
Ataluren treatment of patients with nonsense mutation dystrophinopathyIntroduction: Dystrophinopathy is a ra...
-
Results of North Star Ambulatory Assessments (NSAA) in the Phase 3 Ataluren Confirmatory Trial in Patients with Nons...Objective: Examine the efficacy of atal...
